<!DOCTYPE html>
<html>
	<head>
		<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">

		<meta http-equiv="X-UA-Compatible" content="IE=edge">
		<title>药物警戒法规速递</title>
		<meta name="viewport" content="initial-scale=1, maximum-scale=1">
		<meta name="apple-mobile-web-app-capable" content="yes">
		<meta name="apple-mobile-web-app-status-bar-style" content="black">
		<link rel="stylesheet" href="style.css">
		<link rel="stylesheet" type="text/css" media="screen and (min-device-width: 480px)" href="pcstyle.css">
		<link rel="stylesheet" href="layui/css/layui.css" media="all">
	</head>

	<body>
		<div class="containerBox">
			<div class="containerBox-tabChange">
				<div class="containerBox-tabChange_domestic"><span>药物警戒法规速递</span></div>
			</div>
			<div class="containerBox-tabMain">
				<div class="containerBox-tabMain_domestic" style="">
					<!--法规第二层-->
					<div class="statute">
						<div class="statute-chi"><span>国内法规</span></div>
						<div class="statute-ich"><span>ICH</span></div>
						<div class="statute-fda"><span>FDA</span></div>
						<div class="statute-ema"><span>EMA</span></div>
						<div class="statute-cioms"><span>CIOMS</span></div>
					</div>
					<div class="statuteDetail">
						<!--国内法规-->
						<div class="chiDetail">
							<ul class="chiDetailList commonStyle">
								<li>
									<div class="commonLeft">
										<a href="http://www.nmpa.gov.cn/WS04/CL2138/378032.html">关于发布《国家药监局关于发布药物临床试验必备文件保存指导原则的通告（2020年第37号）》及填表说明的通知</a>
										<p><span>2020-06-08</span><span class="source">[ NMPA ]</span></p>
									</div>
								</li>
								<li>
									<div class="commonLeft">
										<a href="http://www.cdr-adr.org.cn/drug_1/zcfg_1/zcfg_zdyz/202006/t20200604_47472.html">关于发布《关于发布药物警戒委托协议撰写指导原则（试行）的通知》及填表说明的通知</a>
										<p><span>2020-06-04</span><span class="source">[ CDR-ADR ]</span></p>
									</div>
								</li>
								<li>
									<div class="commonLeft">
										<a href="http://www.nmpa.gov.cn/WS04/CL2138/376852.html">关于发布《国家药监局 国家卫生健康委关于发布药物临床试验质量管理规范的公告（2020年第57号）》及填表说明的通知</a>
										<p><span>2020-04-26</span><span class="source">[ NMPA ]</span></p>
									</div>
								</li>
								<li>
									<div class="commonLeft">
										<a href="http://www.cdr-adr.org.cn/drug_1/zcfg_1/zcfg_zdyz/202001/t20200108_47026.html">关于发布《上市许可持有人药品不良反应报告表（试行）》及填表说明的通知</a>
										<p><span>2020-01-08</span><span class="source">[ CDR-ADR ]</span></p>
									</div>
								</li>
								
								<li>
									<div class="drugsDetailList-left commonLeft">
										<a href="http://www.cdr-adr.org.cn/drug_1/zcfg_1/zcfg_zdyz/201912/t20191231_47006.html">关于E2B（R3）电子传输系统上线试运行的通知</a>
										<p><span>2019-12-31</span><span class="source">[ CDR-ADR ]</span></p>
									</div>
								</li>
								<li>
									<div class="chiDetailList-left commonLeft">
										<a href="http://www.npc.gov.cn/npc/c30834/201908/26a6b28dd83546d79d17f90c62e59461.shtml">《中华人民共和国药品管理法》</a>
										<p><span>2019-12-01 </span><span class="source">[ NPC ]</span></p>
									</div>
								</li>
								<li>
									<div class="commonLeft">
										<a href="http://www.cdr-adr.org.cn/center_news/201911/t20191129_46858.html">关于发布药品上市许可持有人药物警戒年度报告撰写指南（试行）的通知 </a>
											<p><span>2019-11-29</span><span class="source">[ CDR-ADR ]</span></p>
									</div>
								</li>
								<li>
									<div class="drugsDetailList-left commonLeft">
										<a href="http://www.nmpa.gov.cn/WS04/CL2199/371413.html">《个例安全性报告E2B(R3)区域实施指南》</a>
										<p><span>2019-11-22</span><span class="source">[ NMPA ]</span></p>
									</div>
								</li>
								<li>
									<div class="commonLeft">
										<a href="http://www.cdr-adr.org.cn/tzgg_home/201911/t20191107_46748.html">关于公开征求对《药物警戒委托协议撰写指导原则（征求意见稿）》意见的通知 </a>
										<p><span>2019-11-07</span><span class="source">[ CDR-ADR ]</span></p>
									</div>
								</li>
								<li>
									<div class="commonLeft">
										<a href="http://www.nmpa.gov.cn/WS04/CL2138/338318.html">关于发布上市药品临床安全性文献评价指导原则（试行）的通告（2019年第27号）</a>
										<p><span>2019-06-18</span><span class="source">[ NMPA ]</span></p>
									</div>
								</li>
								<li>
									<div class="commonLeft">
										<a href="http://www.cdr-adr.org.cn/tzgg_home/201902/t20190201_39656.html">关于发布上市许可持有人直接报告不良反应常见问题问答文件的通知</a>
										<p><span>2019-02-01</span><span class="source">[ CDR-ADR ]</span></p>
									</div>
								</li>
								<li>
										<div class="commonLeft">
											<a href="http://www.nmpa.gov.cn/WS04/CL2138/331214.html">国家药品监督管理局关于药品上市许可持有人直接报告不良反应事宜的公告（2018年第66号）</a>
											<p><span>2019-01-01</span><span class="source">[ NMPA ]</span></p>
										</div>
								</li>
								<li>
									<div class="commonLeft">
										<a href="http://www.nmpa.gov.cn/WS04/CL2138/334011.html">关于发布个例药品不良反应收集和报告指导原则的通告（2018年第131号）</a>
										<p><span>2018-12-19</span><span class="source">[ NMPA ]</span></p>
									</div>
								</li>
								<li>
									<div class="commonLeft">
										<a href="http://www.cdr-adr.org.cn/drug_1/zcfg_1/zcfg_zdyz/201211/t20121123_35783.html">药品定期安全性更新报告审核要点（试行）</a>
										<p><span>2012-11-19</span><span class="source">[ CDR-ADR ]</span></p>
									</div>
								</li>
								<li>
									<div class="commonLeft">
										<a href="http://www.nmpa.gov.cn/WS04/CL2196/323918.html">国家食品药品监督管理局关于印发药品定期安全性更新报告撰写规范的通知</a>
										<p><span>2012-09-06</span><span class="source">[ CFDA ]</span></p>
									</div>
								</li>
								<li>
									<div class="commonLeft">
										<a href="http://www.gov.cn/flfg/2011-05/24/content_1870110.htm">《药品不良反应报告和监测管理办法》中华人民共和国卫生部令第81号</a>
										<p><span>2011-07-01</span><span class="source">[ 卫生部 ]</span></p>
									</div>
								</li>
						    </ul>
							<div class="line"></div>
						</div>
						<!--ICH-->
						<div class="ichDetail">
							<ul class="ichDetailList commonStyle">
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E1/Step4/E1_Guideline.pdf">E1：THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL SAFETY FOR DRUGS INTENDED FOR LONG-TERM TREATMENT OF NON-LIFE-THREATENING CONDITIONS</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="http://www.cde.org.cn/guide.do?method=downloadAtt&amp;codeStr=47&amp;type2=2">E1：人群暴露程度：评价无生命威胁条 件下长期治疗药物的临床安全性</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf">E2A：CLINICAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="http://www.cde.org.cn/guide.do?method=downloadAtt&amp;codeStr=48&amp;type2=2">E2A：临床安全性资料的管理： 加速报告的定义与标准</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="http://estri.ich.org/e2br3/index.htm">E2B（R3）：Individual Case Safety Report (ICSR) Specification and Related File</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="http://www.cde.org.cn/guide.do?method=downloadAtt&amp;codeStr=164&amp;type2=2">E2B（R3）：数据元素和信息规范元素 （中文版：征求意见稿）</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2C/E2C_R2_Step4.pdf">E2C（R2）：PERIODIC BENEFIT-RISK EVALUATION REPORT (PBRER)</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="http://www.cde.org.cn/guide.do?method=downloadAtt&amp;codeStr=50&amp;type2=2">E2C（R2）：定期利益-风险评估报告（PBRER）</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2C/E2CR2_QAs_Step4.pdf">E2C (R2) ：Guideline: Periodic Benefit-Risk Evaluation Report Questions &amp; Answers</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="http://www.cde.org.cn/guide.do?method=downloadAtt&amp;codeStr=51&amp;type2=2">E2C（R2）指南：定期利益-风险评估报告疑问与解答</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf">E2D：POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="http://www.cde.org.cn/guide.do?method=downloadAtt&amp;codeStr=52&amp;type2=2">E2D：上市后安全数据管理：快速报告的定义和标准</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2E/Step4/E2E_Guideline.pdf">E2E：PHARMACOVIGILANCE PLANNING</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="http://www.cde.org.cn/guide.do?method=downloadAtt&amp;codeStr=53&amp;type2=2">E2E：药物警戒计划</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2F/Step4/E2F_Step_4.pdf">E2F：DEVELOPMENT SAFETY UPDATE REPORT</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="http://www.cde.org.cn/guide.do?method=downloadAtt&amp;codeStr=54&amp;type2=2">E2F：研发期间安全性更新报告（中文翻译公开征求意见稿）</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Step_4_2016_1109.pdf">E6(R2) ： INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE</a>
								</div>
								
							</li>
							<li>
								<div class="apparatusDetailList-left commonLeft">
									<a href="http://www.cde.org.cn/guide.do?method=downloadAtt&amp;codeStr=60&amp;type2=2">E6(R1) ：药物临床试验管理规范</a>
								</div>
								
							</li>
							</ul>
							<div class="line"></div>
						</div>
						<!--FDA-->
						<div class="fdaDetail">
							<ul class="fdaDetailList commonStyle">
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071696.pdf">《Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment》</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.govinfo.gov/content/pkg/CFR-2017-title21-vol5/xml/CFR-2017-title21-vol5-sec310-305.xml">Records and reports concerning adverse drug experiences on marketed prescription drugs for human use without approved new drug applications</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.govinfo.gov/content/pkg/CFR-2017-title21-vol5/xml/CFR-2017-title21-vol5-sec312-32.xml">Investigational New Drug Safety Reports</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm477584.pdf">Safety Assessment for IND Safety Reporting</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm477584.pdf">Safety Considerations for Product Design to Minimize Medication Errors</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM331810.pdf">Safety Considerations for Product Design to Minimize Medication Errors</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332846.pdf">Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE StudiesSmall Entity Compliance Guide</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.govinfo.gov/content/pkg/CFR-2017-title21-vol5/xml/CFR-2017-title21-vol5-sec314-80.xml">Postmarketing reporting of adverse drug experiences</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs%20gen/documents/document/ucm295211.pdf">Classifying Significant Postmarketing Drug Safety Issues</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM244570.pdf">Medication Guides — Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM172001.pdf">Postmarketing Studies and Clinical Trials - Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM434188.pdf">Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071981.pdf">Postmarketing Adverse Experience Reporting for Human Drug and Licensed Biological Products: Clarification of What to Report</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM080534.pdf">Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/UCM567959.pdf">Drug and Biologics Safety Surveillance Best Practice Statement Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) US Food and Drug Administration</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM346564.pdf">Providing Postmarketing Periodic Safety Reports in the ICH E2C(R2) Format(Periodic Benefit-Risk Evaluation Report) Guidance for Industry</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM441226.pdf">Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry </a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM244570.pdf">Guidance Medication Guides — Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)</a>
									</div>
								</li>
							</ul>
							<div class="line"></div>
						</div>
						<!--EMA-->
						<div class="emaDetail">
							<ul class="emaDetailList commonStyle">
								<li>
									<div class="commonLeft engfamily">
										<a href="https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32004R0726&amp;qid=1550719950258&amp;from=EN">REGULATION (EC) No 726/2004 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://eurlex.europa.eu/legalcontent/EN/TXT/PDF/?uri=CELEX:32001L0083&amp;qid=1550720600614&amp;from=EN">DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 November 2001 on the Community code relating to medicinal products for human use</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/en/documents/report/guide-interpretation-spontaneous-case-reports-suspected-adverse-reactions-medicines_en.pdf">Guide on the interpretation of spontaneous case reports of suspected adverse reactions to medicines</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32010R1235&amp;qid=1550721314526&amp;from=EN">REGULATION (EU) No 1235/2010 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products (Text with EEA relevance)</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://eur-lex.europa.eu/legalcontent/EN/TXT/PDF/?uri=CELEX:32012R1027&amp;qid=1550727028740&amp;from=EN">REGULATION (EU) No 1027/2012 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 25 October 2012 amending Regulation (EC) No 726/2004 as regards pharmacovigilance (Text with EEA relevance)</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://eur-lex.europa.eu/legalcontent/EN/TXT/PDF/?uri=CELEX:32010L0084&amp;qid=1550726859150&amp;from=EN">DIRECTIVE 2010/84/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use (Text with EEA relevance)</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://eur-lex.europa.eu/legalcontent/EN/TXT/PDF/?uri=CELEX:32012L0026&amp;qid=1550727163871&amp;from=EN">DIRECTIVE 2012/26/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 25 October 2012 amending Directive 2001/83/EC as regards pharmacovigilance (Text with EEA relevance)</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://eur-lex.europa.eu/legalcontent/EN/TXT/PDF/?uri=CELEX:32012R0520&amp;qid=1550727346746&amp;from=EN">COMMISSION IMPLEMENTING REGULATION (EU) No 520/2012 of 19 June 2012 on the performance of pharmacovigilance activities provided for in Regulation (EC) No 726/2004 of the European Parliament and of the Council and Directive 2001/83/EC of the European Parliament and of the Council </a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-12-october-2017_en.pdf">Guidelines on good pharmacovigilance practices (GVP)</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-i-pharmacovigilance-systems-their-quality-systems_en.pdf">Module I – Pharmacovigilance systems and their quality systems</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-ii-pharmacovigilance-system-master-file-rev-2_en.pdf">Module II – Pharmacovigilance system master file (Rev 2) </a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-iii-pharmacovigilance-inspections_en.pdf">Module III – Pharmacovigilance inspections (Rev 1) </a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-iv-pharmacovigilance-audits-rev-1_en.pdf">Module IV – Pharmacovigilance audits (Rev 1)  </a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf">Module V – Risk management systems (Rev 2) </a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf">Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2) </a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vii-periodic-safety-update-report_en.pdf">Module VII – Periodic safety update report (Rev 1) </a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3_en.pdf">Module VIII – Post-authorisation safety studies (Rev 3) </a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf">Module IX – Signal management (Rev 1)</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-x-additional-monitoring_en.pdf">Module X – Additional monitoring</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xv-safety-communication-rev-1_en.pdf">Module XV – Safety communication (Rev 1)</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools_en-3.pdf">Module XVI – Risk minimisation measures: selection of tools and effectiveness indicators (Rev 2) </a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/en/documents/other/european-union-regulatory-network-incident-management-plan-medicines-human-use_en.pdf">The European Union regulatory network incident management plan for medicines for human use</a>
									</div>
								</li>
								<li>
									<div class="commonLeft engfamily">
										<a href="https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practice-guide-risk-minimisation-prevention-medication-errors_en.pdf">Good practice guide on risk minimisation and prevention of medication errors</a>
									</div>
								</li>
							</ul>
							<div class="line"></div>
						</div>
						<!--CIOMS-->
						<div class="ciomsDetail">
							<ul class="ciomsDetailList commonStyle">
								<li>
									<div class="apparatusDetailList-left commonLeft">
										<a href="https://cioms.ch/shop/product/practical-aspects-of-signal-detection-in-pharmacovigilance-report-of-cioms-working-group-viii/">Practical Aspects of Signal Detection in Pharmacovigilance: Report of CIOMS Working Group VIII</a>
									</div>
									
								</li>
								<li>
									<div class="apparatusDetailList-left commonLeft">
										<a href="https://cioms.ch/shop/product/chinese-translation-practical-aspects-signal-detection-pharmacovigilance/">Chinese translation: Practical Aspects of Signal Detection in Pharmacovigilance</a>
									</div>
									
								</li>
								<li>
									<div class="apparatusDetailList-left commonLeft">
										<a href="https://cioms.ch/shop/product/practical-approaches-to-risk-minimisation-for-medicinal-products-report-of-cioms-working-group-ix/">Practical Approaches to Risk Minimisation for Medicinal Products: Report of CIOMS Working Group IX</a>
									</div>
									
								</li>
								<li>
									<div class="apparatusDetailList-left commonLeft">
										<a href="https://cioms.ch/shop/product/council-for-international-organizations-of-medical-sciences-cioms/">Development and Rational Use of Standardised MedDRA Queries (SMQs): Retrieving Adverse Drug Reactions with MedDRA – Second Edition</a>
									</div>
									
								</li>
								<li>
									<div class="apparatusDetailList-left commonLeft">
										<a href="https://cioms.ch/shop/product/development-safety-update-report-dsur-harmonizing-format-content-periodic-safety-report-clinical-trials-report-cioms-working-group-vii/">Development Safety Update Report (DSUR) Harmonizing the Format and Content for Periodic Safety Report during Clinical Trials: Report of CIOMS Working Group VII</a>
									</div>
									
								</li>
								<li>
									<div class="apparatusDetailList-left commonLeft">
										<a href="https://cioms.ch/shop/product/current-challenges-in-pharmacovigilance-pragmatic-approaches-report-of-cioms-working-group-5/">Current Challenges in Pharmacovigilance: Pragmatic Approaches – Report of CIOMS Working Group V</a>
									</div>
									
								</li>
								<li>
									<div class="apparatusDetailList-left commonLeft">
										<a href="https://cioms.ch/wp-content/uploads/2017/01/reporting_adverse_drug.pdf">Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for Their Use</a>
									</div>
									
								</li>
								<li>
									<div class="apparatusDetailList-left commonLeft">
										<a href="https://cioms.ch/shop/product/cioms-guide-vaccine-safety-communication/">CIOMS Guide to Vaccine Safety Communication</a>
									</div>
									
								</li>
								<li>
									<div class="apparatusDetailList-left commonLeft">
										<a href="https://cioms.ch/shop/product/practical-approaches-to-risk-minimisation-for-medicinal-products-report-of-cioms-working-group-ix/">Practical Approaches to Risk Minimisation for Medicinal Products: Report of CIOMS Working Group IX</a>
									</div>
									
								</li>
								<li>
									<div class="apparatusDetailList-left commonLeft">
										<a href="https://cioms.ch/shop/product/benefit-risk-balance-for-marketed-drugs-evaluating-safety-signals/">Benefit-Risk Balance for marketed drugs: Evaluating safety signals</a>
									</div>
									
								</li>
								<li>
									<div class="apparatusDetailList-left commonLeft">
										<a href="https://cioms.ch/shop/product/international-reporting-of-periodic-drug-safety-update-summaries/">International reporting of periodic drug-safety update summaries</a>
									</div>
									
								</li>
							</ul>
							<div class="line"></div>
						</div>
					</div>
				</div>
			</div>

			<div class="foot-exemption">
				<div><a target="_blank" onclick="getDisclaimer();">免责声明</a></div>
			</div>
		</div>


		<script type="text/javascript" src="jquery-3.3.1.min.js"></script>
		<script type="text/javascript" src="layui/layui.js"></script>

		<script>
			layui.use(['layer'], function() {
				var layer = layui.layer //弹层
			})

			var htmlContent = '<div style="background:#FFF; "><div style="padding:20px;"><div ><h1 style="color:#C00; border-bottom:1px solid #C00; text-align:center;padding-bottom:5px;">网站免责声明</h1></div><div style="padding:20px 0px; line-height:1.5;"><p>本网站所提供的信息，只供参考之用。我们对其中的任何资料不作保证，链接来源的提供亦不构成任何法律或其他意见。我们将对本网页上的信息不时更新及修改，但可能未反映最新的发展。</p><p>凡以任何方式进入本网站或直接、间接使用本网站资料者，视为自愿接受本网站声明的约束。</p></div></div></div>';

			function getDisclaimer() {
				layer.open({
					title: '免责声明',
					content: htmlContent,
					type: 1,
					shadeClose : true
				});
			}
			/*设置根元素<html>字体大小*/
			if (document.body.clientWidth <= 480) {
				function getRem() {
					var html = document.getElementsByTagName("html")[0];
					var oWidth = document.body.clientWidth || document.documentElement.clientWidth;
					html.style.fontSize = oWidth / 7.5 + "px";
				}
				window.onload = function() {
					getRem();
					window.addEventListener("resize", getRem, false);
				};
			}
			$().ready(function() {
				$(".containerBox-tabChange>div").click(function() {
					let ind = $(this).index();
					$(".containerBox-tabMain>div").eq(ind).show().siblings().hide();
					$(this).addClass("active").siblings().removeClass("active");
				});
				//二层选项卡
				$(".statute>div").click(function() {
					let _index = $(this).index();
					$(".statuteDetail>div").eq(_index).show().siblings().hide();
					$(this).addClass("active").siblings().removeClass("active");
				});
			});

			$(".statute-chi").click(function() {
				$(".statute-chi").css({
					"background": "#3385ff"
				});
				$(".statute-chi").css({
					"color": "#FFF"
				});
				$(".statute-chi").siblings().css({
					"background": "#eef1f7"
				});
				$(".statute-chi").siblings().css({
					"color": "#333"
				});
			})
			$(".statute-ich").click(function() {
				$(".statute-ich").css({
					"background": "#3385ff"
				});
				$(".statute-ich").css({
					"color": "#FFF"
				});
				$(".statute-ich").siblings().css({
					"background": "#eef1f7"
				});
				$(".statute-ich").siblings().css({
					"color": "#333"
				});
			})
			$(".statute-fda").click(function() {
				$(".statute-fda").css({
					"background": "#3385ff"
				});
				$(".statute-fda").css({
					"color": "#FFF"
				});
				$(".statute-fda").siblings().css({
					"background": "#eef1f7"
				});
				$(".statute-fda").siblings().css({
					"color": "#333"
				});
			})
			$(".statute-ema").click(function() {
				$(".statute-ema").css({
					"background": "#3385ff"
				});
				$(".statute-ema").css({
					"color": "#FFF"
				});
				$(".statute-ema").siblings().css({
					"background": "#eef1f7"
				});
				$(".statute-ema").siblings().css({
					"color": "#333"
				});
			})
			$(".statute-cioms").click(function() {
				$(".statute-cioms").css({
					"background": "#3385ff"
				});
				$(".statute-cioms").css({
					"color": "#FFF"
				});
				$(".statute-cioms").siblings().css({
					"background": "#eef1f7"
				});
				$(".statute-cioms").siblings().css({
					"color": "#333"
				});
			})
		</script>

	</body>
</html>
